Drugs / COH29
COH29
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02112565 | Jun 2016 → Nov 2018 overdue | cancer of unknown primary site | City of Hope Medical Center | Active not recruiting | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | COH29 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02112565 ↗ |
| Known as | City of Hope 29 | “This phase I trial studies the side effects and best dose of RNR Inhibitor City of Hope 29 (COH29) in treating patients with solid tumors that are refractory to standard...” NCT02112565 ↗ |
| Known as | Rnr inhibitor coh29 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297421 ↗ |
| Action | Inhibit | “COH29 may inhibit an enzyme called ribonucleotide reductase” NCT02112565 ↗ |
| Modality | Small molecule | — CHEMBL4297421 ↗ |
| Route | Oral | “COH29 orally (PO)” NCT02112565 ↗ |